CAPRIN2

Across TCGA pan-cancer cohorts, CAPRIN2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CAPRIN2 data layer compared with 29 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher CAPRIN2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CAPRIN2 expression acts as an unfavorable survival marker.

CESC, BRCA, and UCEC are the cancer types where CAPRIN2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.141	0.711	<.001	12	view →
BRCA	OS	Median	III,IV	0.621	0.906	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LIHC	OS	Median	II,III,IV	0.239	0.715	.035	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CAPRIN2–CESC (DFS)

Open the CESC breakdown →